Delivery and fate of oral mesalamine microgranules within the human small intestine.

[1]  S. Hanauer.  Medical therapy of ulcerative colitis , 1993, The Lancet.

[2]  J. Teare,et al.  The mode of action of the aminosalicylates in inflammatory bowel disease , 1993 .

[3]  U. Klotz,et al.  Oroileal transit of slow release 5-aminosalicylic acid. , 1993, Gut.

[4]  S. Hanauer,et al.  Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. , 1993, Gastroenterology.

[5]  G. May,et al.  Sulfasalazine Revisited , 1993, Annals of Internal Medicine.

[6]  R. Modigliani,et al.  Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID) , 1993, Gastroenterology.

[7]  V. Trimble,et al.  Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis , 1992, The Lancet.

[8]  A. Fitton,et al.  Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease. , 1991, Drugs.

[9]  J. Rask-Madsen,et al.  Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. , 1990, Gut.

[10]  B. Norlander,et al.  Pharmacokinetics of a 5‐aminosalicylic acid enteric‐coated tablet in patients with Crohn's disease or ulcerative colitis and in healthy volunteers , 1990, Alimentary pharmacology & therapeutics.

[11]  S. Hansen,et al.  Topical and systemic availability of 5‐amino‐salicylate: comparisons of three controlled release preparations in man , 1990, Alimentary pharmacology & therapeutics.

[12]  D. Giesing,et al.  Effect of food coadministration on 5‐aminosalicylic acid oral suspension bioavailability , 1990, Clinical pharmacology and therapeutics.

[13]  P. Layer,et al.  Feedback regulation of human pancreatic secretion. Effects of protease inhibition on duodenal delivery and small intestinal transit of pancreatic enzymes. , 1990, Gastroenterology.

[14]  P. Layer,et al.  Human pancreatic secretion and intestinal motility: effects of ileal nutrient perfusion. , 1990, The American journal of physiology.

[15]  R. V. van Hogezand,et al.  Disposition of 5-aminosalicylic acid from 5-aminosalicylic acid-delivering drugs during accelerated intestinal transit in healthy volunteers. , 1989, Scandinavian journal of gastroenterology.

[16]  R. N. Brogden,et al.  Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease. , 1989, Drugs.

[17]  B. Norlander,et al.  Pharmacokinetics of a 5‐aminosalicylic acid enteric‐coated tablet and suppository dosage form , 1989, Alimentary pharmacology & therapeutics.

[18]  U. Klotz,et al.  Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease. , 1989, Gastroenterology.

[19]  H. Spiro.  Inflammatory bowel diseases—Basic research and clinical implications , 1989 .

[20]  Ami,et al.  Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. , 1989, BMJ.

[21]  S. Riley,et al.  Delayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects. , 1988, British journal of clinical pharmacology.

[22]  J. Hardcastle,et al.  Measurement of gastrointestinal pH profiles in normal ambulant human subjects. , 1988, Gut.

[23]  J. Elashoff,et al.  Human postprandial gastric emptying of 1-3-millimeter spheres. , 1988, Gastroenterology.

[24]  S. Riley,et al.  Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. , 1988, Gastroenterology.

[25]  P. Wesseling,et al.  Double‐blind comparison of 5‐aminosalicylic acid and acetyl‐5‐aminosalicylic acid suppositories in patients with idiopathic proctitis , 1988, Alimentary pharmacology & therapeutics.

[26]  E. Dimagno,et al.  Human pancreatic secretion during phase II antral motility of the interdigestive cycle. , 1988, The American journal of physiology.

[27]  C. Deighton,et al.  Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis. , 1987, Gut.

[28]  J. Hardy,et al.  Evaluation of an enteric‐coated delayed‐release 5‐aminosalicylic acid tablet in patients with inflammatory bowel disease , 1987, Alimentary pharmacology & therapeutics.

[29]  J. Hardy,et al.  Gastrointestinal transit of an enteric‐coated delayed‐release 5‐aminosalicylic acid tablet , 1987, Alimentary pharmacology & therapeutics.

[30]  L. Sutherland,et al.  5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. , 1987, Gastroenterology.

[31]  A. Richens,et al.  Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. , 1987, Gut.

[32]  A. Zinsmeister,et al.  Effects of decreasing intraluminal amylase activity on starch digestion and postprandial gastrointestinal function in humans. , 1986, Gastroenterology.

[33]  U. Klotz,et al.  Clinical Pharmacokinetics of Sulphasalazine, Its Metabolites and Other Prodrugs of 5-Aminosalicylic Acid , 1985, Clinical pharmacokinetics.

[34]  S. Bondesen,et al.  Kinetics of 5-aminosalicylic acid after jejunal instillation in man. , 1983, British journal of clinical pharmacology.

[35]  U. Klotz,et al.  Specific measurement of 5-aminosalicylic acid and its acetylated metabolite in human bile. , 1983, British journal of clinical pharmacology.

[36]  S. Hansen,et al.  5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. , 1982, Gastroenterology.

[37]  U. Klotz,et al.  Simplified high-performance liquid chromatographic method for 5-aminosalicylic acid in plasma and urine. , 1981, Journal of chromatography.

[38]  S. Truelove,et al.  AN EXPERIMENT TO DETERMINE THE ACTIVE THERAPEUTIC MOIETY OF SULPHASALAZINE , 1977, The Lancet.

[39]  D. Wingate,et al.  A comparison of stable and 14C-labelled polyethylene glycol as volume indicators in the human jejunum 1 , 1972, Gut.

[40]  Raphael Ss,et al.  Deaf-mutism and type-II hyperlipoproteinaemia. , 1970 .

[41]  A. Hofmann,et al.  Simultaneous measurements of total pancreatic, biliary, and gastric outputs in man using a perfusion technique. , 1970, Gastroenterology.

[42]  D. Jewell,et al.  Acetylation of 5-aminosalicylic acid by isolated human colonic epithelial cells. , 1990, Clinical science.

[43]  M. Rijk,et al.  Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds. , 1988, Scandinavian journal of gastroenterology.

[44]  U. Klotz,et al.  A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics. , 1985, Arzneimittel-Forschung.